Mutations in SDHC cause autosomal dominant paraganglioma, type 3
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Nonchromaffin paragangliomas (PGLs) are usually benign, neural-crest-derived, slow-growing tumours of parasympathetic ganglia. Between 10% and 50% of cases are familial and are transmitted as autosomal dominant traits with incomplete and age-dependent penetrance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [4]
In the citing paper
“In 2008, mutation of SDH was discovered in cancers such as paraganglioma and pheochromocytoma cells124. Later, similar observations were made in gastrointestinal tumors, neuroblastomas, renal tumors, thyroid tumors, and testicular tumors125,126.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [126]
Citations
Cites
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
PROSPECTIVE RANDOMISED TRIAL OF EARLY DIETARY PROTEIN RESTRICTION IN CHRONIC RENAL FAILURE
Rosman, J., Ter Wee, P., Meijer Truus, S., Piers-Becht, P. M., Sluiter, W., & Donker, A. M. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90818-3 · Cited by 555
GENOMIC IMPRINTING IN HEREDITARY GLOMUS TUMOURS: EVIDENCE FOR NEW GENETIC THEORY
Van Der Mey, A. L., Maaswinkel-Mooy, P., Cornelisse, C., Schmidt, P., & Van De Kamp, J. P. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91908-9 · Cited by 305
Familial carotid body tumors: Case report and epidemiologic review
Grufferman, S., Gillman, M. W., Pasternak, L. R., Peterson, C. L., & Young, W. G. (1980) · Cancer · doi:10.1002/1097-0142(19801101)46:9<2116::aid-cncr2820460934>3.0.co;2-s · Cited by 240
Heutink, P., Mey, A. G. L. V. D., Sandkuijl, L. A., Gils, A. P. G. V., Bardoel, A., Breedveld, G. J., Vliet, M. V., Ommen, G.-J. B. V., Cornelisse, C. J., Oostra, B. A., et al. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.1.7 · Cited by 214
Mariman, E. C. M., van Beersum, S. E. C., Cremers, C. W. R. J., Struycken, P., & Ropers, H. (1995) · Human Genetics · doi:10.1007/bf00225075 · Cited by 136
Hirawake, H., Taniwaki, M., Tamura, A., Kojima, S., & Kita, K. (1997) · Cytogenetic and Genome Research · doi:10.1159/000134700 · Cited by 62
Repositioning the hereditary paraganglioma critical region on chromosome band 11q23
Baysal, B. E., van Schothorst, E. M., Farr, J. E., Grashoff, P., Myssiorek, D. J., Rubinstein, W. S., Taschner, P. E. M., Cornelisse, C. J., Devlin, B., Devilee, P., et al. (1999) · Human Genetics · doi:10.1007/s004390050939 · Cited by 58
PGL3 , a third, not maternally imprinted locus in autosomal dominant paraganglioma
Niemann, S., Steinberger, D., & Müller, U. (1999) · Neurogenetics · doi:10.1007/s100480050078 · Cited by 54
Self-citation
Cited by
Items 601–700 of 938
Impacts of benzovindiflupyr on the embryonic development of zebrafish ( Danio rerio )
Zhou, Y., Yao, H., Ni, F., Xu, C., & Xu, G. (2018) · Toxicological & Environmental Chemistry Reviews · doi:10.1080/02772248.2019.1587442 · Cited by 12
“…for example, succinateselective accumulation is a universal metabolic signature of ischemia in a range of tissues and is responsible for mitochondrial ROS production during reperfusion (Hatefi 1985; Niemann and M€uller 2000; Yankovskaya et al. 2003; Chouchani et al. 2014; Xiao et al. 2016).”
BackgroundTranslational Research in Endocrine Surgery
Sherman, S. K., & Howe, J. R. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.012 · Cited by 12
MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours
Crona, J., Maharjan, R., Verdugo, A. D., Stalberg, P. L. H., Granberg, D. O., Hellman, P., & Björklund, P. (2013) · Familial Cancer · doi:10.1007/s10689-013-9666-3 · Cited by 12
No difference in phenotype of the main D utch SDHD founder mutations
van Hulsteijn, L. T., den Dulk, A. C., Hes, F. J., Bayley, J., Jansen, J. C., & Corssmit, E. P. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12223 · Cited by 12
Rich, B. S., Moo, T.-A. S., Mark, S., Scognamiglio, T., Pecker, M. S., Sobol, I., LaRocca, G., & Fahey, T. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1969 · Cited by 12
Mitochondrial Disorders Due to Nuclear OXPHOS Gene Defects
Ugalde, C., Morán, M., Blázquez, A., Arenas, J., & Martín, M. A. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-2813-6_7 · Cited by 12
Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism
Tevosian, S. G., & Ghayee, H. K. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01991 · Cited by 12
“ATRX Loss of function (13, 14) CSDE1 Loss of function (15) FH Loss of function (16) HIF2A Gain of function (17–19) HRAS Gain of function (20) IDH1 Gain of function (21) KIF1B Loss of function (22) MAML3 Gain of function (15) MAX Loss of function (23) MDH2 Loss of function (24) MEN2 (RET) Gain of function (25, 26) NF1…”
BackgroundMaster regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations
Smestad, J. A., & Maher, L. J., III (2019) · BMC Cancer · doi:10.1186/s12885-019-5813-z · Cited by 12
Cascón, A., Cebrián, A., Pollán, M., Ruiz‐Llorente, S., Montero‐Conde, C., Letón, R., Gutiérrez, R. J., Lesueur, F., Milne, R. L., Albarrán, O. G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2059 · Cited by 12
No fumarate hydratase (FH) mutations in hereditary prostate cancer
Lehtonen, R., Kiuru, M. H., Rökman, A., Ikonen, T., Cunningham, J. M., Schaid, D. J., Matikainen, M., Nupponen, N. N., Karhu, A., Kallioniemi, O.-P., et al. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.3.e19 · Cited by 12
Rehfus, A. (2018) · University writing server of the University of Hohenheim (Universität Hohenheim) · Cited by 12
Waguespack, S. G., & Fishbein, L. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00015-4 · Cited by 11
Nan, H., Guo, P., Fan, J., Zeng, W., Hu, C., Zheng, C., Pan, B., Cao, Y. J., Ge, Y., Xue, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093974 · Cited by 11
Pitfalls in Genetic Analysis of Pheochromocytomas/Paragangliomas—Case Report
Canu, L., Rapizzi, E., Zampetti, B., Fucci, R., Nesi, G., Richter, S., Qin, N., Giaché, V., Bergamini, C., Parenti, G., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4453 · Cited by 11
Martins, R. G., Gonçalves, L. G., Cunha, N., & Bugalho, M. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01101 · Cited by 11
WANG, H., Wu, Y., WANG, Z., CHEN, Y., MO, J., GUAN, W., ZHANG, Y., & Yao, H. (2021) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.03553 · Cited by 11
Mutation screening in a Norwegian cohort with pheochromocytoma
Sjursen, W., Halvorsen, H., Hofsli, E., Bachke, S., Berge, Å., Engebretsen, L. F., Falkmer, S. E., Falkmer, S., & Varhaug, J. E. (2013) · Familial Cancer · doi:10.1007/s10689-013-9608-0 · Cited by 11
“This observation is in accordance with the results of other investigations [33], except for one recent case of a SDHC mutation found in a PHEO patient [34].”
Jandová, J., Eshaghian, A., Shi, M., Li, M., King, L. E., Janda, J., & Sligh, J. E. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.320 · Cited by 11
“…M anuscript and mutations in subunits of the succinate dehydrogenase gene (SDHB, SHDC, SDHD) have been associated with paragangliomas, pheochromocytomas and renal cell carcinomas (Baysal et al., 2000; Niemann and Muller 2000; Astuti et al., 2001; Lehtonen et al., 2004; Vanharanta et al., 2004).”
BackgroundKokko, A., Ylisaukko‐oja, S. K., Kiuru, M. H., Takatalo, M. S., Salmikangas, P., Tuimala, J., Arango, D., Karhu, A., Aaltonen, L. A., & Jäntti, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21423 · Cited by 11
Familial endocrine tumours: phaeochromocytomas and extra-adrenal paragangliomas
Komminoth, P., Perren, A. A., van Nederveen, F. H., & de Krijger, R. R. (2009) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2009.01.003 · Cited by 11
Metabolism of Cell Growth and Proliferation
DeBerardinis, R. J., & Thompson, C. B. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10014-7 · Cited by 11
The Metabolic Basis of Kidney Cancer
Srinivasan, R., George, A. K., & Linehan, W. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-17903-2_6 · Cited by 11
p53 Alterations and Their Relationship to SDHD Mutations in Parasympathetic Paragangliomas
van Nederveen, F. H., Dannenberg, H., Sleddens, H. F. B. M., de Krijger, R. R., & Dinjens, W. N. M. (2003) · Modern Pathology · doi:10.1097/01.mp.0000084111.03922.4d · Cited by 11
“Since then, mutations in other subunits, B (SDHB) and C (SDHC) of complex II, have also been found to predispose to paraganglioma development (8, 9).”
Multiple pheochromocytomas and paragangliomas in a young patient carrying a SDHD gene mutation
Novosel, A., Heger, A., Lohse, P., & Schmidt, H. (2004) · European Journal of Pediatrics · doi:10.1007/s00431-004-1538-2 · Cited by 11
“Only two families with a SDHCmutation have been reported; one with a paraganglioma and one with a pheochromocytoma [9, 10].”
BackgroundHart, M. L., Sokolov, D., Danquah, S., Zheng, E., Doan, A. D., Davidsen, K., MacPherson, D. P., & Sullivan, L. B. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01524-w · Cited by 11
Tsoli, M., Daskalakis, K., Kassi, E. N., Kaltsas, G., & Tsolakis, A. V. (2021) · Biology · doi:10.3390/biology10070580 · Cited by 10
“8% SDHC [50] Pseudoxypoxia Germline PGL Low * SDHD [44,46,48] Pseudoxypoxia Germline PGL 0–31.”
BackgroundHuang, B.-L., Liu, Q., Teng, Y.-Y., Peng, S., Liu, Z., Li, M., Liang, J., Zhang, Y., & Wang, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1167796 · Cited by 11
“(22) (total link strength = 9,427), Lenders Jacques w.”
BackgroundPhenotype of SDHB mutation carriers in the Netherlands
van Hulsteijn, L. T., Niemeijer, N. D., Hes, F. J., Bayley, J., Tops, C. M. J., Jansen, J. C., & Corssmit, E. P. M. (2014) · Familial Cancer · doi:10.1007/s10689-014-9738-z · Cited by 10
“encoding subunits A, B, C, D or assembly factor 2 of the mitochondrial complex II-succinate dehydrogenase (SDH) [3–7], TMEM127 or MAX [8, 9].”
MethodWang, C., Chen, T., Chang, Y., Ko, J., Yang, T., Lo, F., Hu, Y., Chen, P., Wu, C., & Lou, P. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.08.025 · Cited by 10
Carotid body tumors are not associated with an increased risk for sleep-disordered breathing
van Hulsteijn, L. T., van Duinen, N., Ninaber, M. K., Romijn, J. A., van Dijk, J. G., van Kralingen, K. W., Havekes, B., Smid, L., Lammers, G. J., Jansen, J. C., et al. (2013) · Sleep And Breathing · doi:10.1007/s11325-013-0855-y · Cited by 10
“Germline mutations in subunits A, B, C, D, or assembly factor 2 of the succinate dehydrogenase (SDH) gene cause familial PGLs [2–6].”
BackgroundShuch, B. M., Mmonu, N. A., Ricketts, C. J., Vocke, C. D., Gautam, R., Merino, M. J., Linehan, W. M., & Srinivasan, R. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.0214 · Cited by 10
Jochmanová, I., & Lazúrová, I. (2014) · Biomedical Papers · doi:10.5507/bp.2014.021 · Cited by 10
Tokuyama, T., Ahmed, R. E., Chanthra, N., Anzai, T., & Uosaki, H. (2021) · Biology · doi:10.3390/biology10100981 · Cited by 10
“Heterozygous variants in SDHB, SDHC, and SDHD cause dominantly inherited paragangliomas and pheochromocytomas [70,71].”
BackgroundParaganglioma: The role of genetic counselling and radiological screening
Dundee, P. E., Clancy, B., Wagstaff, S. M., & Briggs, R. (2005) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2004.04.010 · Cited by 10
Molecular genetic aspects and pathophysiology of endocrine hypertension
Fountoulakis, S., & Tsatsoulis, A. A. (2006) · HORMONES · doi:10.14310/horm.2002.11173 · Cited by 10
Hoekstra, A. S., van den Ende, B., Julià, X. P., van Breemen, L., Scheurwater, K., Tops, C. M. J., Malinoc, A., Devilee, P., Neumann, H. P. H., & Bayley, J.-P. (2016) · Clinical Genetics · doi:10.1111/cge.12843 · Cited by 10
“Germline mutations in the genes that encode succinate dehydrogenase (SDH), including SDHA (3), SDHB (4), SDHC (5), SDHD (6), and SDHAF2 (7), are associated”
BackgroundFernández‐Cruz, L., Puig‐Domingo, M., Halperín, I., & Sesmilo, G. (2004) · Scandinavian Journal of Surgery · doi:10.1177/145749690409300409 · Cited by 10
Carotid Body Tumors in Humans Caused by a Mutation in the Gene for Succinate Dehydrogenase D (SDHD)
Dahan, A., Taschner, P. E. M., Jansen, J. C., van der Mey, A. G. L., Teppema, L. J., & Cornelisse, C. J. (2004) · Advances in experimental medicine and biology · doi:10.1007/0-387-27023-x_12 · Cited by 10
Neurological and molecular biological characterisation of the mutant mouse line Tom40
Zeh, R. (2013) · Cited by 10
Histopathology of Parasellar Neoplasms
Manojlović-Gačić, E., Rostami, E., Karavitaki, N., & Casar‐Borota, O. (2020) · Neuroendocrinology · doi:10.1159/000507084 · Cited by 9
Oishi, Y., Nagai, S., Yoshida, M., Fujisawa, S., Sazawa, A., Shinohara, N., Nonomura, K., Matsuno, K., & Shimizu, C. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-023 · Cited by 9
Domingues, R., Montalvão, P., Magalhães, M. J., Santos, R. M., Duarte, L., & Bugalho, M. J. (2012) · PubMed · doi:10.3275/8237 · Cited by 9
Tumor strengths and frailties: Cancer SUMmOns Otto's metabolism
Ohh, M. (2012) · Nature Medicine · doi:10.1038/nm.2631 · Cited by 9
Over-representation of the G12S polymorphism of the SDHD gene in patients with MEN2A syndrome
Lendvai, N. K., Tóth, M., Valkusz, Z., Bekő, G., Szücs, N., Csajbók, É., Igaz, P., Kriszt, B., Kovács, B., Rácz, K., et al. (2012) · Clinics · doi:10.6061/clinics/2012(sup01)15 · Cited by 9
Maher, E. R. (2006) · British Medical Bulletin · doi:10.1093/bmb/ldl002 · Cited by 9
Balasubramanian, G., & Nellaiappan, V. (2014) · BMJ Case Reports · doi:10.1136/bcr-2013-203425 · Cited by 9
Pheochromocytoma - A New View of the Old Problem
Vilela-Martin, J. F. (2011) · InTech eBooks · doi:10.5772/1278 · Cited by 9
Wallace, D. C., Lott, M. T., & Procaccio, V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00013-6 · Cited by 9
Genetics of pheochromocytoma and paraganglioma
Benn, D. E., Marsh, D. J., & Robinson, B. G. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200202000-00010 · Cited by 9
Novel SDHD germ‐line mutations in pheochromocytoma patients
Neumayer, C., Moritz, A., Asari, R., Weinhäusel, A., Hölzenbein, T., Kretschmer, G., Niederle, B., & Haas, O. A. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01822.x · Cited by 9
Molecular Genetics of Kidney Cancer
Zimmer, M., & Iliopoulos, O. (2003) · Cancer treatment and research · doi:10.1007/978-1-4615-0451-1_1 · Cited by 9
An apparently sporadic paraganglioma with an SDHB gene germline mutation presenting at age 68 years
Elston, M. S., Benn, D. E., Robinson, B. G., & Conaglen, J. V. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01023.x · Cited by 9
Pugh, C. W. (2003) · Annals of Medicine · doi:10.1080/07853890310017062 · Cited by 9
“Mitochondrial Toolbox” – A Review of Online Resources to Explore Mitochondrial Genomics
Cappa, R., de Campos, C. P., Maxwell, A. P., & McKnight, A. J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00439 · Cited by 8
“SDHB mutations have been identified in Familial renal cell carcinoma patients (Ricketts et al., 2008), SDHC mutations in cases of autosomal dominant paraganglioma type 3 (Niemann and Muller, 2000) and a case of epithelial thyroid cancer combined with carotid paraganglioma (Zbuk et al., 2007).”
BackgroundSarkadi, B., Likó, I., Nyírő, G., Igaz, P., Butz, H., & Patócs, A. (2021) · Cancers · doi:10.3390/cancers13164219 · Cited by 8
Rakheja, D., Khokhar, S., Mitui, M., & Cost, N. G. (2012) · Pediatric and Developmental Pathology · doi:10.2350/12-01-1151-oa.1 · Cited by 8
Janecke, A., Willett-Brozick, J. E., Karas, C., Hasipek, M., Löffler‐Ragg, J., & Baysal, B. E. (2010) · Journal of Human Genetics · doi:10.1038/jhg.2009.142 · Cited by 8
Bronchial Paraganglioma with SDHB Deficiency
Ghigna, M., Dorfmüller, P., Crutu, A., Fadel, É., & de Montpréville, V. (2016) · Endocrine Pathology · doi:10.1007/s12022-016-9422-y · Cited by 8
Silva, L. F. O., Skiados, N. G., Murugavel, N., Cover, K., Luna, N., Gupta, M., Contreras, S. C., O’Brien, T. E., & Zhang, W. C. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04002-7 · Cited by 7
Diagnosis and Management of Hereditary Phaeochromocytoma and Paraganglioma
Lalloo, F. I. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-29998-3_7 · Cited by 7
Lin, D., Lin, J., Li, X., Zhang, J., Lai, P., Mao, Z., Zhang, L., Zhu, Y., & Liu, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01181 · Cited by 7
Hashizume, O., Yamanashi, H., Taketo, M. M., Nakada, K., & Hayashi, J.-I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118561 · Cited by 7
Du, X., Wan, S., Chen, Y., Qü, P., Huang, X., Yu, X., Yang, H., Zhang, Y., & Xing, J. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3876-2 · Cited by 7
Metastatic pheochromocytomas and paragangliomas: where are we?
Prinzi, N., Corti, F., Torchio, M., Niger, M., Antista, M., Pagani, F., Beninato, T., Pulice, I., Rossi, R. E., Coppa, J. C., et al. (2022) · Tumori Journal · doi:10.1177/03008916221078621 · Cited by 7
A Case of Malignant Pheochromocytoma with Holt-Oram Syndrome
Yoshihara, A., Tanabe, A., Saito, H., Hizuka, N., Ishizawa, A., Horikawa, R., & Takano, K. (2008) · Endocrine Journal · doi:10.1507/endocrj.k07e-011 · Cited by 7
Role of SDHAF2 and SDHD in von Hippel–Lindau Associated Pheochromocytomas
Kugelberg, J., Welander, J., Schiavi, F., Fassina, A., Bäckdahl, M., Larsson, C., Opocher, G., Söderkvist, P., Dahia, P. L. M., Neumann, H. P. H., et al. (2013) · World Journal of Surgery · doi:10.1007/s00268-013-2373-2 · Cited by 7
“The vast majority of affected patients belong to one of the following syndromes: von Hippel– Lindau (VHL) [5], multiple endocrine neoplasia type 2 (MEN 2) [6], von Recklinghausen (NF1) [7], or PCC–PGL syndrome (PGL types 1–4) [8–11], which are caused by germline mutations in VHL, RET, NF1, and SDHx (SDHA, SDHB, SDHC,…”
BackgroundInfluentialAnatomy, physiology, and genetics of paragangliomas
Kim, Y., & Goldenberg, D. (2015) · Operative Techniques in Otolaryngology-Head and Neck Surgery · doi:10.1016/j.otot.2015.12.003 · Cited by 7
Pheochromocytoma and multiple endocrine neoplasia syndromes
Waguespack, S. G., & Ying, A. K. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00023-8 · Cited by 7
Genetic Syndromes Associated with Adrenal Tumors
Åkerström, G., & Hellman, P. (2005) · Springer eBooks · doi:10.1007/3-540-26861-8_25 · Cited by 7
Garibaldi, E., Bresciani, S., Panaia, R., Delmastro, E., Malinverni, G., & Gabriele, P. (2011) · Tumori Journal · doi:10.1177/030089161109700214 · Cited by 7
Das, P., & Guha, G. (2010) · Journal of Scientific Research · doi:10.3329/jsr.v3i1.5078 · Cited by 7
Barbolosi, D., Crona, J., Serre, R., Pacák, K., & Taïeb, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201303 · Cited by 7
“Association between the TCA cycle and PPGL was later confirmed by the identification of mutations in other genes encoding subunits B [5], C [6], and A [7] of the SDH complex or its flavination factor (SDHAF2) [8] and more recently, mutations in fumarate hydratase [9] and malate dehydrogenase type 2 [10].”
BackgroundTrading mtDNA uncovers its role in metastasis
Ishikawa, K., & Hayashi, J. (2009) · Cell Adhesion & Migration · doi:10.4161/cam.3.1.6838 · Cited by 6
Sarkadi, B., & Patócs, A. (2019) · Experientia supplementum · doi:10.1007/978-3-030-25905-1_8 · Cited by 6
Braun, M. M., Damjanac, T., Zhang, Y., Chen, C., Hu, J., & Maher, L. J., III (2019) · PLoS ONE · doi:10.1371/journal.pone.0227033 · Cited by 6
Prasad, P. K., Kant, J. A., Wills, M. L., O’Leary, M. F., Lovvorn, H. N., & Yang, E. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.04.009 · Cited by 6
“Loss-of-function mutations as a cause of familial paraganglioma were first identified in the SDHD gene, and subsequently in the SDHC and SDHB genes [2–4,7].”
BackgroundFamilial pheochromocytomas and paragangliomas: Stories from the sign-out room
Perren, A. A., & Komminoth, P. (2006) · Endocrine Pathology · doi:10.1007/s12022-006-0005-1 · Cited by 6
Yamashita, R., Usui, T., Hashimoto, S., Suzuki, H., Takahashi, M., Honkura, K., Iwamoto, K., KODAMA, E., Tagami, T., Naruse, M., et al. (2009) · Endocrine Journal · doi:10.1507/endocrj.k09e-111 · Cited by 6
Krebs cycle enzymes as tumor suppressors
Baysal, B. E. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.05.012 · Cited by 6
Tracy, J. C., & Wein, R. O. (2012) · Head & Neck · doi:10.1002/hed.23098 · Cited by 6
Clinical Report on the L95P Mutation in a Dutch Family with Paraganglioma
Cremers, C. W. R. J., de Mönnink, J. P., Arts, N., Joosten, F. B. M., Kremer, H., & Hoefsloot, L. H. (2002) · Otology & Neurotology · doi:10.1097/00129492-200209000-00024 · Cited by 6
“The pattern of inheritance is autosomal dominant, and three different genetic types of paraganglioma have been recognized based on gene linkage and mutation analysis: paraganglioma 1 PGL1 (11q23) (1), paraganglioma 2 PGL2 (11q13) (2), and paraganglioma 3 PGL3 (3).”
BackgroundInfluentialAntibody-based approaches to diagnosis and characterization of oxidative phosphorylation diseases
Hanson, B. J., Marusich, M. F., & Capaldi, R. (2001) · Mitochondrion · doi:10.1016/s1567-7249(01)00026-5 · Cited by 6
Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects
Taïeb, D., Timmers, H. J. L. M., & Pacák, K. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0586-3710 · Cited by 5
Ishii, T., Yasuda, K., Miyazawa, M., Onouchi, H., Yanase, S., & Ishii, N. (2025) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.25-62 · Cited by 5
Molecular diagnostics and mitochondrial dysfunction: a future perspective
Siciliano, G., Pasquali, L., Mancuso, M., & Murri, L. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.4.531 · Cited by 5
Sarkadi, B., Grolmusz, V. K., Butz, H., Kövesdi, A., Likó, I., Nyírő, G., Igaz, P., & Patócs, A. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.31036 · Cited by 5
“Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3.”
InfluentialBruce‐Brand, C., & van Wyk, A. C. (2020) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2020.1838161 · Cited by 5
Sato, H., Kanai, G., Hirabayshi, K., Kajiwara, H., Itoh, J., & OSAMURA, R. Y. (2010) · Endocrine · doi:10.1007/s12020-010-9365-x · Cited by 5
Avoiding and Nonexpressing: Coping Styles of Patients With Paragangliomas
van Hulsteijn, L. T., Kaptein, A. A., Louisse, A., Smit, J. W. A., & Corssmit, E. P. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1340 · Cited by 5
Paragangliomas, caracterização clínica e funcional de 40 casos
Santos, R. M., Domingues, R., Montalvão, P., Magalhães, M. J., & Bugalho, M. J. (2011) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/2011.000010.000140 · Cited by 5
“Desde que é conhecida a relação entre os genes que codificam as subunidades da enzima Succinato Desidrogenase (SDH) e a etiologia dos PGLs que o diagnóstico genéti-co nos doentes com estes tumores assumiu particular importância na abordagem e seguimento dos mesmos 8,9,10 .”
Mitochondrial Calcium Signalling: Role in Oxidative Phosphorylation Diseases
Oulès, B., Prete, D., & Mouni, C. (2012) · InTech eBooks · doi:10.5772/32117 · Cited by 5
“Very interestingly, two groups independently reported mutations of the complex II subunit D and C genes in hereditary paraganglioma — usually benign, vascularized tumours in the head and in the neck (Baysal et al., 2000; Niemann & Muller, 2000).”
BackgroundPheochromocytoma and Paraganglioma
Meyer-Rochow, G. Y., & Sidhu, S. B. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0857-5_9 · Cited by 5
SDHD-Related Chromaffin Tumours: Disease Localisation to Genetic Dysfunction
Srirangalingam, U., Khoo, B. C. E., Matson, M. B., Carpenter, R., Reznek, R. H., Maher, E. R., Chew, S. L., & Drake, W. M. (2010) · Hormone Research in Paediatrics · doi:10.1159/000277659 · Cited by 5
Pheochromocytoma and the Multiple Endocrine Neoplasia Syndromes
Chernausek, S. D., & Eng, C. (2008) · Elsevier eBooks · doi:10.1016/b978-141604090-3.50018-1 · Cited by 5
Chapter 3 Molecular Genetic Basis of the Mitochondrial Encephalomyopathies
Schon, E. A., Hirano, M., & DiMauro, S. (2002) · Blue books of practical neurology · doi:10.1016/s1877-3419(09)70062-5 · Cited by 5
Rare vertebral metastasis in a case of Hereditary Paraganglioma
da Silva, M. E. R., Carvalho, M. J. Q. D. F. S., Rodrigues, A. P. C., Nevès, N., Gonçalves, A. M., Pinto, R. A. P., & Carvalho, D. M. (2012) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-10-12 · Cited by 4
“Investigation has revealed that SDHD mutations [PGL type 1] are associated with multifocal head and neck paragangliomas, whereas SDHB mutations [PGL type 4] are associated with extra-adrenal disease and malignancy [8,9].”
BackgroundSequencing of a central nervous system tumor demonstrates cancer transmission in an organ transplant
Gingras, M., Sabo, A., Cardenas, M., Rana, A. A., Dhingra, S., Meng, Q., Hu, J., Muzny, D. M., Doddapaneni, H., Perez, L. M., et al. (2021) · Life Science Alliance · doi:10.26508/lsa.202000941 · Cited by 4
“…prognosis (Tanaka et al, 2019); SDHC mutations are found in paragangliomas 3 (PGL3), a neural crest tumor that can develop at various body sites (Niemann & Müller, 2000); and mutations in DDR2 , a member of the collagen receptor family and a receptor tyrosine kinase, have been identi fi ed in a…”
Shi, C., Liu, J., Zeng, Z.-P., Miao, Q., Fang, L., Chen, S., Ping, F., Sun, H., Lü, L., Chen, L., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad093 · Cited by 4
An autopsy case of bilateral adrenal pheochromocytoma-associated cerebral hemorrhage
Mizukami, H., Hara, S., Kobayashi, M., Mori, S., Kuriiwa, F., & Fukunaga, T. (2012) · Legal Medicine · doi:10.1016/j.legalmed.2012.08.007 · Cited by 4
Molecular Imaging in Hereditary Succinate Dehydrogenase Mutation–Related Paragangliomas
Marzola, M. C., & Rubello, D. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000572 · Cited by 4
Metadata
- Authors
- Niemann, S., & Müller, U.
- Affiliations
- Justus-Liebig-Universität Gießen (DE)
- Corresponding author
- Müller, Ulrich
- ORCID
- Müller, Ulrich
- Venue
- Nature Genetics
- Published
- 2000-11
- Volume
- 26
- Issue
- 3
- Pages
- 268-270
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1528834211
- Cited by
- 875
- References
- 9
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 9 · 2023: 18 · 2022: 14 · 2021: 24 · 2020: 24 · 2019: 35 · 2018: 27 · 2017: 36 · 2016: 36 · 2015: 44 · 2014: 59 · 2013: 49 · 2012: 72
- FWCI
- 32.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- SDHC, nonchromaffin paraganglioma, autosomal dominant inheritance, familial paraganglioma, neural crest tumors, parasympathetic ganglia, penetrance
- MeSH terms
- Chromosomes, Human, Pair 1, DNA Mutational Analysis, Female, Genes, Dominant, Humans, Male, Membrane Proteins, Mitochondria, Molecular Sequence Data, Multienzyme Complexes, Neoplastic Syndromes, Hereditary, Oxidoreductases, Paraganglioma, Pedigree, Succinate Dehydrogenase, Mutagenesis, Site-Directed, DNA, Complementary, Protein Subunits, Electron Transport Complex II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.